Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The child is 4 years to 14 years of age~* The child is a non smoker~* The child has exercise-induced bronchoconstriction (EIB)~Exclusion Criteria:~* The child has active or chronic breathing disease, other than asthma~* The child has required insertion of a breathing tube for asthma~* The child had major surgery within the last 4 weeks~* The child is currently in the hospital~* The child has or had an upper respiratory tract infection within the last 2 weeks~* The child has been hospitalized or visited the emergency room or had a change in their medication for asthma within the last 4 weeks~* The child has been in a research study in the last 4 weeks~* The child has stomach, brain, heart, kidney or liver disease~* The child drinks more that 4 caffeinated drinks a day

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast Sodium (Type: EXPERIMENTAL): Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period
- Placebo (Type: EXPERIMENTAL): Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period

Based on this trial design, predict the completion outcome and termination type (if applicable).